SecBot SecBot

IMA drug pipeline

ImageneBio, Inc. · 1 rated drug
$3.20
−7.8% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 2b
Time to marketIf the Phase 2b ADAPTIVE trial (topline Q4 2027) succeeds, a Phase 3 program would follow, meaning potential approval is likely several years away, probably no earlier than 2029-2030.

olevaprubart Updated Nov 12

What to watch

The next hard catalyst is the Phase 2b ADAPTIVE topline readout in atopic dermatitis, expected in Q4 2027, over a year away. In the nearer term, watch for initiation of the Phase 2 alopecia areata study by year-end 2026 and any early efficacy signals. The OX40 competitive landscape is shifting rapidly with Sanofi's amlitelimab setback and AbCellera's exit, which could be a relative positive for olevaprubart's positioning.

Bull case
  • Olevaprubart is a potential first-in-class non-T cell-depleting, ADCC-silenced anti-OX40 antagonist with an extended half-life, which could offer a differentiated safety and dosing profile versus competitors like rocatinlimab (T-cell depleting).
  • Phase 2a data in atopic dermatitis showed rapid, marked, and durable improvement with a well-tolerated profile and no Kaposi sarcoma cases across all trials, addressing a key safety concern for the class.
  • Sanofi's abandonment of amlitelimab and AbCellera's OX40 exit reduce competitive noise, potentially widening olevaprubart's commercial opportunity if Phase 2b succeeds.
Bear case
  • The Phase 2b ADAPTIVE topline readout is not expected until Q4 2027, leaving the stock without a near-term binary catalyst for over a year, which creates a long period of data-free drift.
  • The OX40 class is crowded and has seen setbacks: Sanofi abandoned amlitelimab approval efforts in atopic dermatitis (July 2026), and AbCellera exited the space (Nov 2026), raising questions about the commercial viability of the mechanism.
  • Rocatinlimab (Amgen/Kyowa Kirin) has already reported positive Phase 3 ROCKET data, potentially establishing a competitive benchmark that olevaprubart must match or exceed.